Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety study of regorafenib (BAY 73-4506) in hepatocellular carcinoma
2009-012570-13Phase 2Completed
- Sponsor
- Bayer
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoint: Safety. Started Jul 2009; status: completed.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-012570-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012570-13.